VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 356 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2016. The put-call ratio across all filers is 1.00 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $48,868,000 | -28.3% | 2,427,903 | -6.3% | 2.07% | -18.9% |
| Q1 2016 | $68,166,000 | -75.1% | 2,591,399 | -4.0% | 2.55% | -72.0% |
| Q4 2015 | $274,083,000 | -21.3% | 2,698,614 | +38.2% | 9.09% | -22.2% |
| Q3 2015 | $348,097,000 | -9.3% | 1,952,983 | +13.0% | 11.69% | -6.2% |
| Q2 2015 | $383,849,000 | +1.9% | 1,728,265 | -9.0% | 12.46% | -3.6% |
| Q1 2015 | $376,646,000 | +46.6% | 1,898,540 | +5.8% | 12.93% | +32.4% |
| Q4 2014 | $256,978,000 | +7.8% | 1,794,227 | -1.2% | 9.77% | +6.1% |
| Q3 2014 | $238,296,000 | +18.7% | 1,815,916 | +12.4% | 9.20% | +12.5% |
| Q2 2014 | $200,765,000 | -5.7% | 1,615,549 | +0.1% | 8.18% | -11.6% |
| Q1 2014 | $212,826,000 | +9.3% | 1,614,593 | -2.7% | 9.26% | +0.0% |
| Q4 2013 | $194,668,000 | +12.3% | 1,658,555 | -0.1% | 9.26% | -0.1% |
| Q3 2013 | $173,348,000 | +21.2% | 1,660,917 | -0.0% | 9.27% | +9.7% |
| Q2 2013 | $142,981,000 | – | 1,661,625 | – | 8.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACCIPITER CAPITAL MANAGEMENT, LLC | 2,106,379 | $55,398,000 | 31.67% |
| Claren Road Asset Management, LLC | 80,000 | $2,820,000 | 24.27% |
| Okumus Fund Management Ltd. | 3,722,464 | $97,901,000 | 15.82% |
| Wingspan Investment Management, LP | 852,900 | $22,431,000 | 12.66% |
| FARLEY CAPITAL L.P. | 307,458 | $8,086,000 | 11.46% |
| Chou Associates Management | 976,843 | $25,725,000 | 8.35% |
| Wingspan Investment Management, LP | 550,700 | $14,483,000 | 8.17% |
| HAP Trading, LLC | 4,043,900 | $109,610,000 | 8.00% |
| LeVasseur Capital Partners LLC | 128,269 | $3,373,000 | 6.97% |
| Pershing Square Capital Management | 21,591,122 | $567,847,000 | 6.41% |